Business Wire

International Energy Disputes Partner David Hesse Joins Hunton Andrews Kurth in London

Share

David Hesse, an energy disputes attorney whose practice focuses on oil and gas litigation and arbitration matters with a strong emphasis on Africa has joined Hunton Andrews Kurth LLP as a partner in London.

Hesse advises states and national oil and gas companies on disputes, settlements, and upstream activities, as well as international tenders, refinery projects, farm-out agreements, and other contracts in the petroleum and petrochemical industries. His practice includes international commercial arbitration matters involving Anglophone and Francophone states and state entities in North, East, Central and West Africa.

Previously a partner with Clyde & Co., Hesse joins longtime colleague and collaborator Philip Mace as the newest additions to Hunton Andrews Kurth’s London-based energy team. Mace, who also recently joined the firm as a partner from Clyde & Co., is an experienced corporate lawyer whose practice is focused on energy and upstream oil and gas transactions.

“Robust global demand for large scale energy and infrastructure projects and the natural proliferation of disputes associated with those ventures continue to drive the need for a strong international arbitration and litigation practice,” said Tom Taylor, co-head of Hunton Andrews Kurth’s litigation team. “David is an outstanding lawyer whose experience and ability to navigate complex international disputes make him an ideal complement to the team.”

Hesse has extensive experience before international institutions including the International Chamber of Commerce (ICC) and International Centre for Settlement of Investment Disputes (ICSID). A selection of his notable representations prior to joining the firm include:

  • Advised the Government of Tanzania and the Tanzanian Electric Supply Company Limited (TANESCO) as co-lead international counsel with a local firm, in connection with related contract and treaty claims (ICSID) by Standard Chartered Bank.
  • Advised the Nigerian National Petroleum Corporation (NNPC) and supporting Nigerian counsel in connection with over $1 billion in claims by China National Offshore Oil Corporation (CNOOC) and South Atlantic Petroleum (SAPETRO) under a production sharing contract.
  • Advised the Government of Algeria and Sonatrach in connection with parallel proceedings (ICSID and UNCITRAL) by an oil and gas exploration company and an international shipping and logistics company for claims in excess of $8 billion relating to Algeria’s Windfall Profit Tax.
  • Advised the Government of Uganda and the Uganda Revenue Authority in connection with a $405 million claim by Heritage Oil (UNCITRAL) and a $473 million claim by Tullow Oil plc (ICSID) for recovery of capital gains tax under a production sharing agreement.
  • Advised ZCCM Investment Holdings PLC in connection with $2 billion in claims by Vedanta Resources Holdings Limited (UNCITRAL) relating to Konkola Copper Mines plc in Zambia.

“David’s practice complements our London-based projects and corporate offerings and reinforces our internationally recognized strength in the energy sector,” said Ferdinand Calice, managing partner of Hunton Andrews Kurth’s London office. “We are excited to welcome David to the firm.”

A recognized lawyer in Chambers Global and Legal 500, Hesse is also an Honorary Lecturer at the Centre for Energy, Petroleum and Mineral Law and Policy at the University of Dundee and a lecturer at the CWC School for Energy. He is a regular speaker at international arbitration and energy conferences, including Juris Conference, GAR Energy Disputes, and GAR Live.

Hesse received his undergraduate degree from the University of Cincinnati, his LLB (Maîtres) from the Universitie de Paris – La Sorbonne, and his LLM from Columbia Law School.

Hunton Andrews Kurth’s international arbitration and transnational litigation practice represents clients around the globe. We regularly handle investor-state arbitrations before the International Centre for Settlement of Investment Disputes (ICSID), and commercial arbitrations before the International Court of Arbitration of the International Chamber of Commerce (ICC); the London Court of International Arbitration (LCIA); the Singapore International Arbitration Centre (SIAC); the Permanent Court of Arbitration in The Hague; and the American Arbitration Association (AAA) and its international division, the International Centre for Dispute Resolution (ICDR). We also work with clients in multi-jurisdictional matters, working closely with counsel in local forums.

About Hunton Andrews Kurth LLP

With over 900 lawyers in the United States, Asia, Europe and the Middle East, Hunton Andrews Kurth LLP is a global firm that serves clients across a broad range of complex transactional, litigation and regulatory matters. The firm is known for its strength in the energy, financial services, real estate, and retail and consumer products industries, as well as its considerable experience in more than 100 distinct areas of practice, including privacy and cybersecurity, intellectual property, environmental, and mergers and acquisitions.

###

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

The PR Office
hak@theproffice.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t

Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye